Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. reports a fourth patient with a confirmed partial response in their Phase 2a ACCENT trial for advanced pancreatic cancer, testing their drug narmafotinib combined with chemotherapy. With this progress, the company is now just two confirmed responses shy of the required six to expand the trial. The trial’s success thus far aligns with Amplia’s positive clinical and preclinical data, with further updates to follow as patient recruitment continues.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
